Hemcheck's Newsletter - Summer 2021

Welcome to the Summer Newsletter from Hemcheck

The first half of 2021 has been eventful for Hemcheck. Despite the pandemic we have been able to make progress and continue developing the company on many fronts.
We started the year with a successful directed share issue to secure funding for the company, which is very important. We have then had one clear focus on new recruitments and we have during the spring hired four full time employees, two of which will start in August.
On the commercial side we have made clear progress. We have spent significant time and effort on the training of staff and setup of the instruments etc at Capio S:t Göran during the first months of the year.

We have also been taking steps in establishing Hemcheck in new markets by signing agreements with distributors in the Middle East, Indonesia, Ireland and Croatia, as well as starting and completing additional studies, with the recent positive results from Barcelona in Spain as one example.
The collaborations with Medicen in France, and Medscaler in the Netherlands, are also continuing where they are helping Hemcheck to set up local customer meetings. More tests and studies are planned or ongoing with other centers and potential customers. You can read more about some of these developments happening during June, further down.

The annual trade fairs are now also opening up for physical participation, which is very positive and will further improve our ability to market our products. In the near future we are e.g. planning on participating at IFBLS in Denmark.

On other fronts it’s also very important to mention that we have filed a new patent application regarding a product system for the blood gas market and we are continuing our work with the new product for the blood gas market. These developments are very important for Hemcheck, and we hope our current patent applications will be approved.

All said, we have made a lot of progress during the first half of 2021, and we are looking forward to a continued and hopefully accelerated development and progress during the autumn.
With this, I would like to wish all readers a pleasant summer!

Joen Averstad, CEO

Evaluation agreement signed regarding potential distribution, UAE

Hemcheck has signed a 5-month evaluation agreement with potential continuation into a 25-month long distribution agreement with Gulf Drug LLC (”Gulf Drug”), one of the leading distributors of medical equipment in the UAE. The agreement is formed to evaluate the collaboration and market opportunity, and will be exclusive for the UAE market, should the evaluation be successful according to both parties. Gulf Drug has committed to an initial purchase order of readers and one-time tests for a value of 8,000 EUR, should the agreement be extended after the 5-month evaluation period.

Read more

Hemcheck starts evaluation at the Liverpool Heart and Chest Hospital

Hemcheck is starting a collaboration with Liverpool Heart and Chest Hospital to assess the potential clinical use of Hemcheck’s products related to cardiac surgeries performed at the hospital. The evaluation will be performed over the next 6 months.

Read more


Distribution agreement signed regarding the Indonesian market

Hemcheck has signed an exclusive distribution agreement with PT Setia Guna Medika, a leading distributor of laboratory and medical equipment in Indonesia. The agreement is valid until the end of March 2023, concerning the Indonesian market. PT Setia Guna Medika has committed to an initial purchase order of readers and one-time tests for a value of 8,000 EUR.

Read more

Hemcheck_logo_line_preview 2

Upcoming events 2021

August 24th

September 6th
POCT: Making the point

Contact Us
Hemcheck Sweden AB
Karlstads universitet
Universitetsgatan 2
651 88 Karlstad